This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Matfin, G. Search for Related Content Social Bookmarking                         What's this?

Review: Biomarkers in clinical trials and drug development: measurement of cardiometabolic risk

Division of Endocrinology and Diabetes, Department of Medicine, New York University School of Medicine, New York, USA, gnnm{at}novonordisk.com

Cardiometabolic risk is linked to a cluster of modifiable factors, including established risk factors such as obesity, dyslipidaemia, raised blood pressure, and 'nontraditional' risk factors closely related to central (especially intra-abdominal) adiposity. These 'nontraditional' risk factors include dysfunction of inflammation, coagulation, platelets, fibrinolysis, lipoproteins, endothelium, plaque instability, and miscellaneous biological processes. Both the established ('traditional') and emerging ('nontraditional') cardiometabolic risk factors are components of the metabolic syndrome.

In patients with known or suspected cardiometabolic diseases, biomarkers are increasingly being explored as indicators of disease presence, severity or activity, prognosis and therapeutic efficacy. Many biomarkers have been proposed for prediction of the macrovascular (and microvascular) complications of cardiometabolic diseases. This review provides background information on biomarkers, and an assessment of the possible utility of biomarkers in clinical trials and drug development programmes that include measurement of cardiometabolic risk.

Key Words: biomarker • cardiometabolic risk • clinical end point • diabetes • metabolic syndrome • surrogate end point

References

• Vasan RS Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:1335-62.[Abstract/Free Full Text]
• Biomarkers Definitions Working Group. Biomarkers and surrogate end points: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Europ Heart J 2007;28:88-136.[Free Full Text]
• Fonseca V. Risk factors for coronary heart disease in diabetes. Ann Intern Med 2000;133:154-6.[Free Full Text]
• Eckel R., Grundy S., Zimmet P. Metabolic syndrome. Lancet 2005; 365:1415-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Koenig W., Khuseyinova N. Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26.[Abstract/Free Full Text]
• Ridker PM, Brown NJ, Vaughan DE et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109:(suppl 4) 6-19.[CrossRef][Web of Science]
• Musunuru K., Abraham J., Blumenthal RS Criteria for clinical use of biomarkers. Endocrine 2006;4:6-9.
• Mora S., Rrfai N., Ridker PM Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 2006;114:381-7.[Abstract/Free Full Text]
• Hansson GK Inflammation, Atherosclerosis, and Coronary Artery Disease. N Eng J Med 2005;352:1685-95.[Free Full Text]
• L Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.[Free Full Text]
• Lloyd-Jones DM, Liu K., Tian L. et al. Narrative Review: Assessment of CReactive Protein in Risk Prediction for Cardiovascular Disease. Ann Intern Med 2006;145:35-42.[Abstract/Free Full Text]
• Kohler HP, Grant PJ Plasminogen-activator inhibitor type 1 and coronary artery disease. N Eng J Med 2000;342:1792-801.[Free Full Text]
• Kershaw EE, Flier JS Adipose tissue as an endocrine organ. J Clin Endo Metab 2004;89:2548-56.[Abstract/Free Full Text]
• Schulze MB, Rimm EB, Shah I. et al. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004;27:1680-7.[Abstract/Free Full Text]
• Yu JG, Javorschi S., Havener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-74.[Abstract/Free Full Text]
• Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocyte and vascular function. J Clin Endo Metab 2004;89:2563-8.[Abstract/Free Full Text]
• Cowie MR B-type natriuretic peptide testing: where are we now? Heart 2004;90:725-6.[Abstract/Free Full Text]
• Konstam MA Natriuretic Peptides and Cardiovascular Events - More Than a Stretch. JAMA 2007;297:212-14.[Free Full Text]
• Tarnow L., Gall MA, Hansen BC et al. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006;49:2256-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bell DSH. Heart failure in diabetes. Diabetes Care 2003;26:2433-41.[Abstract/Free Full Text]
• Nesto RW, Bell D., Bonoe RO et al. Thiazolidinediones use, fluid retention, and congestive heart failure. Diabetes Care 2004;27:256-63.[Free Full Text]
• Wang TJ, Gona P., Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Eng J Med 2006;355:2631-9.[Abstract/Free Full Text]
• Ridker PM, Buring JE, Rifai N., Cook NR Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007;297:611-19.[Abstract/Free Full Text]
• Psaty BM, Furberg CD Rosiglitazone and cardiovascular risk. N Eng J Med 2007,10.1056/NEJME078099 (accessed at www.nejm.org, May 21st, 2007).

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3, 101-106 (2007)
DOI: 10.1177/14746514070070030201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Matfin Aspects of drug development and clinical trials -- Part 2 The British Journal of Diabetes & Vascular Disease, July 1, 2007; 7(4): 149 - 150. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Matfin, G. Search for Related Content Social Bookmarking                         What's this?